Covalon Receives European Patent for Drug Delivery Method Using Liposomes within Therapeutic Collagen-based Hydrogels

May 02, 2005

Mississauga, Ontario – 2 May, 2005: Covalon Technologies Ltd. (Covalon) (TSX Venture: COV) is extremely pleased to announce that it has received European Patent protection for drug delivery technology concerning using liposomes within collagen-based hydrogel.

The technology can be used as a drug delivery platform involving the retention of a drug within liposomes which are microscopic spheres of lipid designed to act as time-release drug depots. The patent augments Covalon’s technology position in the expanding area of convergent medical devices.  The medical devices that may benefit form the technology include wound dressings, implantable medical devices and wound closure systems useful for helping to reduce hospital acquired infection. The type of therapeutic agent that can be encapsulated within the liposomes is not restricted to a single type of antiseptic or combination of one or more of these. The hydrogel composition might comprise a variety of active agents and include antibiotics, hormones, growth factors and other factors that are beneficial for the medical condition under management.

Covalon Technologies Ltd,. is an advanced medical biosystems company that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings.  Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.

For further information please contact:    
William Jackson, Chief Financial Officer,
Covalon Technologies Ltd.
T: (905) 568-8400
F: (905) 568-5200
www.covalon.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.  The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.

This document contains forward-looking statements. These statements relate to future events or future performance. In some cases, forward-looking statements can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of any of these terms or comparable terminology. Such statements reflect  the current views of management of the Company with respect to future events. Actual events or results may differ materially. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any any obligation to up0date any such factors or  to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.